发布求助
文献互助 智能选刊 最新文献

Melanoma Management最新文献

筛选
英文 中文
Early palliative care in metastatic uveal melanoma (early together): protocol of a prospective randomized Phase III trial 转移性葡萄膜黑色素瘤的早期姑息治疗（早期共同治疗）：前瞻性随机III期试验方案
IF 1
Melanoma Management Pub Date : 2024-08-08 DOI: 10.1080/20450885.2024.2382080
Sophie Piperno-Neumann, Leanne de Koning, T. Marchal, L. Gastaud, Lorraine Waechter, A. Fogliarini, Carole Bouleuc, Yves Libert, R. Seban, L. Thery, Agnes Ducoulombier, Manuel Rodrigues, A. Brédart, Alexia Savignoni, S. Dolbeault, A. Burnod
{"title":"Early palliative care in metastatic uveal melanoma (early together): protocol of a prospective randomized Phase III trial","authors":"Sophie Piperno-Neumann, Leanne de Koning, T. Marchal, L. Gastaud, Lorraine Waechter, A. Fogliarini, Carole Bouleuc, Yves Libert, R. Seban, L. Thery, Agnes Ducoulombier, Manuel Rodrigues, A. Brédart, Alexia Savignoni, S. Dolbeault, A. Burnod","doi":"10.1080/20450885.2024.2382080","DOIUrl":"https://doi.org/10.1080/20450885.2024.2382080","url":null,"abstract":"","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141926179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A clinical impact study of dermatologists' use of diagnostic gene expression profile testing to guide patient management. 皮肤科医生使用基因表达谱诊断测试指导患者管理的临床影响研究。
IF 3.6
Melanoma Management Pub Date : 2024-05-09 eCollection Date: 2024-01-01 DOI: 10.2217/mmt-2023-0002
Alexander Witkowski, Abel D Jarell, Kelli L Ahmed, Jennifer J Siegel, Brooke H Russell, Jason H Rogers, Matthew S Goldberg, Neil F Fernandes, Joanna Ludzik, Aaron S Farberg
{"title":"A clinical impact study of dermatologists' use of diagnostic gene expression profile testing to guide patient management.","authors":"Alexander Witkowski, Abel D Jarell, Kelli L Ahmed, Jennifer J Siegel, Brooke H Russell, Jason H Rogers, Matthew S Goldberg, Neil F Fernandes, Joanna Ludzik, Aaron S Farberg","doi":"10.2217/mmt-2023-0002","DOIUrl":"10.2217/mmt-2023-0002","url":null,"abstract":"<p><p><b>Aim:</b> Cutaneous melanocytic neoplasms with diagnostic and/or clinical ambiguity pose patient management challenges. <b>Methods:</b> Six randomized case scenarios with diagnostic/clinical uncertainty were described with/without a benign or malignant diagnostic gene expression profile (GEP) result. <b>Results:</b> Clinical impact was assessed by reporting the mean increase/decrease of management changes normalized to baseline (n = 32 dermatologists). Benign GEP results prompted clinicians to decrease surgical margins (84.2%). Malignant GEP results escalated surgical excision recommendations (100%). A majority (72.2%) reduced and nearly all (98.9%) increased follow-up frequency for benign or malignant GEP results, respectively. There was an overall increase in management plan confidence with GEP results. <b>Conclusion:</b> Diagnostic GEP tests help guide clinical decision-making in a variety of diagnostically ambiguous or clinicopathologically discordant scenarios.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11131342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary malignant melanoma of the genitourinary tract: case series of a rare form of primary mucosal melanoma. 泌尿生殖道原发性恶性黑色素瘤：罕见的原发性粘膜黑色素瘤病例系列。
IF 3.6
Melanoma Management Pub Date : 2024-03-25 eCollection Date: 2024-02-01 DOI: 10.2217/mmt-2023-0009
Olanrewaju Olapeju, Jonathan Shakesprere, Carie Boykin, Patrick Bacaj, Mohamad Salkini, Joanna Kolodney
{"title":"Primary malignant melanoma of the genitourinary tract: case series of a rare form of primary mucosal melanoma.","authors":"Olanrewaju Olapeju, Jonathan Shakesprere, Carie Boykin, Patrick Bacaj, Mohamad Salkini, Joanna Kolodney","doi":"10.2217/mmt-2023-0009","DOIUrl":"https://doi.org/10.2217/mmt-2023-0009","url":null,"abstract":"<p><p>Primary malignant melanoma of the genitourinary tract is extremely rare. We present two such cases in elderly Caucasian females. An 81-year-old female with urinary retention and polypoid urinary bladder mass and a 72-year-old female with gross hematuria and urethral caruncle. After thorough evaluation, they were both eventually diagnosed with primary urogenital melanoma (SOX10 and MART1-positive in tumor cells). In both cases, the presence of melanoma-<i>in</i>-<i>situ</i> and absence of primary melanoma in other sites were consistent with primary urogenital melanoma. Immunotherapy with PD-1 inhibitors and use of neoadjuvant and adjuvant treatment are promising, as treatment guidelines remain unclear and overall survival is low. Additional clinical reporting of primary urogenital melanomas can help in better understanding and ultimately treating it.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10988545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140874899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disulfidptosis-related classification patterns and tumor microenvironment characterization in skin cutaneous melanoma. 皮肤黑色素瘤中与二硫化相关的分类模式和肿瘤微环境特征。
IF 3.6
Melanoma Management Pub Date : 2024-01-12 eCollection Date: 2023-06-01 DOI: 10.2217/mmt-2023-0006
Li Yang, Zi-Jian Cao, Yuan Zhang, Jin-Ke Zhou, Jun Tian
{"title":"Disulfidptosis-related classification patterns and tumor microenvironment characterization in skin cutaneous melanoma.","authors":"Li Yang, Zi-Jian Cao, Yuan Zhang, Jin-Ke Zhou, Jun Tian","doi":"10.2217/mmt-2023-0006","DOIUrl":"10.2217/mmt-2023-0006","url":null,"abstract":"<p><strong>Aim: </strong>To identify distinct disulfidptosis-molecular subtypes and develop a novel prognostic signature.</p><p><strong>Methods/materials: </strong>We integrated into this study multiple SKCM transcriptomic datasets from the Cancer Genome Atlas database and Gene Expression Omnibus dataset. The consensus clustering algorithm was applied to categorize SKCM patients into different DRG subtypes.</p><p><strong>Results: </strong>Three distinct DRG subtypes were identified, which were correlated to different clinical outcomes and signaling pathways. Then, a disulfidptosis-relaed signature and nomogram were constructed, which could accurately predict the individual OS of patients with SKCM. The high-risk group was less sensitive to immunotherapy than the low-risk group.</p><p><strong>Conclusion: </strong>The signature can assist healthcare professionals in making more accurate and individualized treatment choices for patients with SKCM.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10789442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139479557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Organ-sparing central pelvic compartment resection for the treatment of vulvo-vaginal melanomas. 治疗外阴阴道黑色素瘤的中央盆腔保留器官切除术。
IF 3.6
Melanoma Management Pub Date : 2024-01-12 eCollection Date: 2023-09-01 DOI: 10.2217/mmt-2023-0001
Mark McGowan, Brent O'Carrigan, Filipe Correia Martins, Krishnayan Haldar, Pubudu Pathiraja
{"title":"Organ-sparing central pelvic compartment resection for the treatment of vulvo-vaginal melanomas.","authors":"Mark McGowan, Brent O'Carrigan, Filipe Correia Martins, Krishnayan Haldar, Pubudu Pathiraja","doi":"10.2217/mmt-2023-0001","DOIUrl":"10.2217/mmt-2023-0001","url":null,"abstract":"<p><p>Vulvo-vaginal melanomas are one of the rarest gynecological oncology diseases with a poor survival compared with other malignancies. The 5-year survival varies from 13% to 32.3%. Vulvo-vaginal melanomas involving the upper 2/3rds of the vagina are usually treated with total pelvic exenteration (TPE). TPE surgery carries a 50% risk of major complications and also morbidity associated with double stomas. Central pelvic compartment resection is a novel organ-sparing surgical approach entailing radical total laparoscopic hysterectomy, bilateral salpingo-oophrectomy, laparoscopic vaginectomy and vulvectomy to reduce morbidity compared with TPE. Permanent suprapubic catheters are used if there is urethral involvement but require quality of life studies to assess their long-term outcomes.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10789441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139479567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of BRAF mutations in cutaneous melanoma: histopathological and molecular analysis of a Ukrainian population. 皮肤黑色素瘤中 BRAF 突变的发生率：对乌克兰人群的组织病理学和分子分析。
IF 3.6
Melanoma Management Pub Date : 2023-12-21 eCollection Date: 2023-03-01 DOI: 10.2217/mmt-2023-0005
Oleksandr Dudin, Ozar Mintser, Nazarii Kobyliak, Dmytro Kaminskyi, Roman Shabalkov, Alina Matvieieva, Olga Sukhanova, Antonina Kalmykova, Denys Kozakov, Artem Mashukov, Oksana Sulaieva
{"title":"Incidence of <i>BRAF</i> mutations in cutaneous melanoma: histopathological and molecular analysis of a Ukrainian population.","authors":"Oleksandr Dudin, Ozar Mintser, Nazarii Kobyliak, Dmytro Kaminskyi, Roman Shabalkov, Alina Matvieieva, Olga Sukhanova, Antonina Kalmykova, Denys Kozakov, Artem Mashukov, Oksana Sulaieva","doi":"10.2217/mmt-2023-0005","DOIUrl":"10.2217/mmt-2023-0005","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to investigate the incidence of <i>BRAF</i> mutation in cutaneous melanoma in the Ukrainian population with respect to clinical and histopathological data.</p><p><strong>Materials & methods: </strong>This single-center retrospective cohort study enrolled 299 primary CM with known <i>BRAF</i> status assessed by RT-PCR.</p><p><strong>Results: </strong>The overall <i>BRAF</i> mutation rate was 56.5% in CM and demonstrated a link with the younger age (p < 0.001), anatomical site (p < 0.001) and histological type of CM (p = 0.022). <i>BRAF</i>-positive CM possessed a slightly higher mitotic rate (p = 0.015) and Breslow thickness (p = 0.028) but did not relate to tumor-infiltrating lymphocytes.</p><p><strong>Conclusion: </strong>The high rate of <i>BRAF</i> mutations in CM patients in the Ukrainian cohort was associated with superficial spreading histology, higher depth of invasion and proliferation.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10784762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139467160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary esophageal melanoma: a case report. 原发性食管黑色素瘤1例报告。
IF 3.6
Melanoma Management Pub Date : 2022-12-01 DOI: 10.2217/mmt-2022-0002
Pooja Patel, Colton Boudreau, Samuel Jessula, Madelaine Plourde
{"title":"Primary esophageal melanoma: a case report.","authors":"Pooja Patel,&nbsp;Colton Boudreau,&nbsp;Samuel Jessula,&nbsp;Madelaine Plourde","doi":"10.2217/mmt-2022-0002","DOIUrl":"https://doi.org/10.2217/mmt-2022-0002","url":null,"abstract":"<p><p>Primary esophageal melanoma remains a rare entity with less than 350 case reports noted in the current literature. This diagnosis is associated with a poor prognosis and early detection and management remains fundamental. In this report, we examine the case of an 80-year-old female who presented with a 1-year course of progressive dysphagia and weight loss. Investigations revealed a primary esophageal melanoma with no evidence of metastases. Pathology did not identify any targetable markers for systematic therapy and thus the patient successfully underwent a minimally invasive esophagectomy. Her postoperative course involved endoscopic esophageal dilatations due to an anastomotic stricture, as well as primary lung adenocarcinoma treated with radiotherapy but has otherwise remained without evidence of melanoma recurrence after 25 months from her surgery.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/84/mmt-09-63.PMC10291394.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10086021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uveal melanoma patient attitudes towards prognostic testing using gene expression profiling. 葡萄膜黑色素瘤患者对使用基因表达谱进行预后检测的态度。
IF 3.6
Melanoma Management Pub Date : 2022-09-16 eCollection Date: 2022-09-01 DOI: 10.2217/mmt-2022-0003
Basil K Williams, Jennifer J Siegel, Katherina M Alsina, Lauren Johnston, Amanda Sisco, Kyleigh LiPira, Sara M Selig, Peter G Hovland
{"title":"Uveal melanoma patient attitudes towards prognostic testing using gene expression profiling.","authors":"Basil K Williams,&nbsp;Jennifer J Siegel,&nbsp;Katherina M Alsina,&nbsp;Lauren Johnston,&nbsp;Amanda Sisco,&nbsp;Kyleigh LiPira,&nbsp;Sara M Selig,&nbsp;Peter G Hovland","doi":"10.2217/mmt-2022-0003","DOIUrl":"https://doi.org/10.2217/mmt-2022-0003","url":null,"abstract":"<p><strong>Aim: </strong>This study explored uveal melanoma patient experiences and regret following molecular prognostic testing using a 15-gene expression profile (GEP) test.</p><p><strong>Materials & methods: </strong>A retrospective, cross-sectional survey study was conducted through an online questionnaire capturing patient-reported experiences with prognostic biopsy/molecular testing.</p><p><strong>Results: </strong>Of 177 respondents, 159 (90%) wanted prognostic information at diagnosis. Most 15-GEP-tested patients who shared their results (99%) reported gaining value from testing, as did patients tested with other methods. Patients who received prognostic testing experienced lower decision regret than those who opted out. Decision regret did not differ based on GEP class.</p><p><strong>Conclusion: </strong>Most uveal melanoma patients desire prognostic testing and gain value from the GEP, independent of a high- or low-risk result.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2022-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c8/d2/mmt-09-62.PMC9490505.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33477752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Successful electrochemotherapy treatment of a large bleeding lymph node melanoma metastasis. 成功的电化疗治疗大出血淋巴结黑色素瘤转移。
IF 3.6
Melanoma Management Pub Date : 2022-06-30 eCollection Date: 2022-06-01 DOI: 10.2217/mmt-2021-0006
Fredrik J Landström, Frida E Jakobsson, Stefan J Kristiansson
{"title":"Successful electrochemotherapy treatment of a large bleeding lymph node melanoma metastasis.","authors":"Fredrik J Landström,&nbsp;Frida E Jakobsson,&nbsp;Stefan J Kristiansson","doi":"10.2217/mmt-2021-0006","DOIUrl":"https://doi.org/10.2217/mmt-2021-0006","url":null,"abstract":"<p><p>Despite the progress in immunotherapy and targeted therapy for patients with cutaneous malignant melanoma not all patients with loco-regional recurrences will respond to treatment. Electrochemotherapy is a relatively new treatment modality where the efficacy of a chemotherapeutic drug is enhanced by an electrical field. Here we report a case of a 68-year-old woman with a large therapy resistant inguinal lymph node melanoma metastasis complicated by bleeding that was successfully treated with electrochemotherapy.</p>","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/24/mmt-09-61.PMC9260494.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40591874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma BRAF V600阴性晚期黑色素瘤双免疫检查点抑制剂与单免疫检查点抑制物相比总生存率提高
IF 3.6
Melanoma Management Pub Date : 2022-03-01 DOI: 10.2217/mmt-2021-0005
A. Kartolo, Cynthia Yeung, M. Kuksis, W. Hopman, T. Baetz
{"title":"Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma","authors":"A. Kartolo, Cynthia Yeung, M. Kuksis, W. Hopman, T. Baetz","doi":"10.2217/mmt-2021-0005","DOIUrl":"https://doi.org/10.2217/mmt-2021-0005","url":null,"abstract":"Aim: To evaluate the efficacy of dual versus single immune checkpoint inhibitors (ICI) in BRAF wild-type advanced melanoma patients. Materials & methods: A retrospective study of all advanced BRAF wild-type melanoma patients on palliative-intent ICI between 2015 and 2020 (n = 67). Results: Dual ICI had better overall survival (OS) when compared with single ICI in BRAF wild-type patients (hazard ratio: 0.204; 95% CI: 0.064–0.649; p = 0.007), but lost its statistical significance (median OSl not reached vs 20.9 months; p = 0.213; adjusted hazard ratio: 0.475; 95% CI: 0.164–1.380; p = 0.171) when only including patients treated after 2018 when dual ICI was funded in our province. Dual ICI were significantly associated with more frequent (p = 0.005) and severe (p = 0.026) immune-related adverse events, and required more immune-related adverse events-indicated systemic corticosteroid use (p < 0.001) compared with single ICI. Conclusion: While limited by small sample size and retrospective nature, dual ICI may have non statistically significant trend toward better OS efficacy when compared with single ICI in BRAF V600 wild-type advanced melanoma patients.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46747801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信